Tempest Therapeutics (NASDAQ: TPST) Stock SKYROCKETS Ahead Of Game-Changing Study Results! Will It Soar Or Crash?
It’s a Wild Ride for TPST Investors as Clinical-Stage Oncology Company Teases Breakthrough Data! Investors are on the edge of their seats as Tempest Therapeutics (NASDAQ: TPST) sets the stage for a potentially game-changing announcement. The clinical-stage oncology company has teased the release of updated study results from their Phase 1b/2 combination study of TPST-1120 … Read more